Low
₹264.15
High
₹281.60
| Previous Close | ₹266.85 |
|---|---|
| Day's Range | ₹264.15 - ₹281.60 |
| Open | ₹277.00 |
| 52 Week Range | ₹216.95 - ₹448.80 |
| Volume | 13,292 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 36.25 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.37 |
| Price/Earning (TTM) | 38.55 |
| TTM EPS (₹) | 6.95 |
| P/E Ratio | 93.43 |
| Book Value(₹) | 1.34 |
| PAT Margin (%) | 4.03 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.77 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 411.42 | 1723.86 |
| Expenses | N/A | N/A |
| PBT | 34.78 | 168.88 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 25.23 | 132.98 |
| Founded | 1993 |
|---|---|
| NSE Symbol | MEDICAMEQ |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,53,750.23 | 1,891.15 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,116.76 | 6,856.20 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,313.88 | 4,474.05 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,19,400.22 | 8,313.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,225.36 | 1,401.65 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,10,037.00 | 1,319.00 | 1,148.40 - 1,148.40 |
| Max Healthcare Institute Ltd. | 1,06,234.43 | 1,091.55 | 903.00 - 903.00 |
| Lupin Ltd. | 1,04,489.83 | 2,287.25 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 1,04,265.97 | 1,036.20 | 835.50 - 835.50 |
| Mankind Pharma Ltd. | 1,03,844.60 | 2,506.70 | 1,909.70 - 1,909.70 |
No Records Found
Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Medicamen Biotech has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, May 27, 2026 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to consider and approve the following business(s): 1. The Audited Financial Results of the Company (Standalone and Consolidated) for the quarter / year ended on March 31, 2026 2. To consider the recommendation of Final Dividend on Equity Shares of the Company for the financial year 2025-26, if any. 3. To consider and appoint SPB & Co, Cost Accountants, as the Cost Auditor of the company for the financial year 2026-27. 4. To consider and appoint Cheena & Associates, as the Internal Auditor of the company for the financial year 2026-27. 5. Any other business with the permission of the chair. Further, in accordance with the SEBI (Prevention of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Company's securities was closed from April 1, 2026 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.
.The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Medicamen Biotech Ltd. is ₹266.85 as of 2026-05-21.
The market capitalisation of Medicamen Biotech Ltd. is ₹363.28 as of 2026-05-21.
The 1-year return of Medicamen Biotech Ltd. is 0.00% as of 2026-05-21.
The P/E ratio of Medicamen Biotech Ltd. is 93.43 as of 2026-05-22.
The 52-week high and low of Medicamen Biotech Ltd. are ₹448.80 and ₹216.95, respectively, as of 2026-05-21.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.